Abstract: An improved method and kit of determining whether a patient is predisposed to having severe periodontal disease and/or having high risk of progression of periodontal disease, comprising the steps of (i) taking a biological sample from said patient; (ii) genotyping said biological sample for genetic polymorphism pattern comprising IL 1B (rs16944), IL 1B (rs1143623) and IL 1B (rs4848306); and (iii) comparing said genetic polymorphism patterns to a reference composite genotype pattern; wherein the similarity of said genetic polymorphism patterns to said reference pattern indicate said patient's predisposition to having severe periodontal disease and/or having high risk of progression of periodontal disease.

Abstract: The invention provides methods and compositions relating to identification and use of genetic information from the IL-I gene cluster—including the structure and organization of novel IL-I-like genes found within the IL-I locus as well as polymorphisms and associated haplotypes within these genes. The invention thereby expands the repertoire of useful genetic information available from the IL-I locus—which contains the previously-identified IL-1?, EL-1? and IL-IRN genes, for predicting IL-I associated phenotypes (e.g. increased or decreased risks of inflammatory disease) and for treating IL-I haplotype associated inflammatory phenotypes.

Abstract: The invention provides methods and compositions relating to identification and use of genetic information from the IL-1 gene cluster—including the structure and organization of novel IL-1-like genes found within the IL-1 locus as well as polymorphisms and associated haplotypes within these genes. The invention thereby expands the repertoire of useful genetic information available from the IL-1 locus—which contains the previously-identified IL-1?, IL-1? and IL-1RN genes, for predicting IL-1 associated phenotypes (e.g. increased or decreased risks of insulin resistance associated pathologies) and for treating IL-1 haplotype associated insulin resistance associated pathologies.

Abstract: Diagnostics and therapeutics for resistance to weight-loss, which are based upon the identification of a subject's PLIN polymorphisms, haplotype and genotype pattern, are described in this invention.

Abstract: The kits and methods of the present invention relate to the diagnosis of cardiovascular disorders. In one aspect, the invention discloses a method and a kit for determining whether a subject has a fragile plaque disorder. In one aspect, the invention discloses a method and a kit for determining whether the subject has an occlusive disorder. In one aspect, the invention discloses a method and a kit for determining whether the subject has a restenosis disorder. Other methods of the present invention relate to the selection of therapeutics for a patient with a cardiovascular disease.

Abstract: This application relates to methods and tests that allow for the establishment of personalized weight-loss programs for a subject based upon the subject's metabolic genotype in key metabolic genes. Kits and methods are disclosed for determining a subject's metabolic genotype, which may be used to select an appropriate therapeutic/dietary regimen or lifestyle recommendation based upon the likelihood of a subject's responsiveness to certain diets and activity levels. Such a personalized weight-loss program will have obvious benefits (e.g., yield better results in terms of weight loss and weight maintenance) over traditional weight-loss programs that do not take into account genetic information.

Abstract: This application relates to methods and kits for detecting predisposition to increased risk for osteoarthritis associated conditions.

Abstract: Diagnostics and therapeutics for osteoporosis, which are bases upon the identification of a subjects IL-1 haplotype and genotype pattern are described.

Abstract: This application relates to methods and tests that allow for the establishment of personalized weight-loss programs for a subject based upon the subject's metabolic genotype in key metabolic genes. Kits and methods are disclosed for determining a subject's metabolic genotype, which may be used to select an appropriate therapeutic/dietary regimen or lifestyle recommendation based upon the likelihood of a subject's responsiveness to certain diets and activity levels. Such a personalized weight-loss program will have obvious benefits (e.g., yield better results in terms of weight loss and weight maintenance) over traditional weight-loss programs that do not take into account genetic information.

Abstract: This application relates to methods and tests that allow for the establishment of personalized weight-loss programs for a subject based upon the subject's metabolic genotype in key metabolic genes. Kits and methods are disclosed for determining a subject's metabolic genotype, which may be used to select an appropriate therapeutic/dietary regimen or lifestyle recommendation based upon the likelihood of a subject's responsiveness to certain diets and activity levels. Such a personalized weight-loss program will have obvious benefits (e.g., yield better results in terms of weight loss and weight maintenance) over traditional weight-loss programs that do not take into account genetic information.

Abstract: A system and method for facilitating personal weight management based on genetic markers. Genetic samples can be analyzed and genotype patterns can be identified and provided to a user. Wellness information, including macronutrient requirements and exercise requirements, based on genotype patterns can be generated. Genotype patterns and wellness information can be stored, transmitted and displayed via computer networks and the internet. Existing third party diets, meal plans, and/or fitness programs can be recommended based on the genotype patterns. Individuals can use nutritional tracking software and/or exercise metric programs coupled with their genetic information to make adjustments to their diet and/or exercise to lose weight. Individuals can purchase nutrition products based on their genotype information.

Abstract: This application relates to methods and kits for detecting predisposition to increased risk for osteoarthritis associated conditions.

Abstract: The invention provides methods and compositions for the pharmacogenetic analysis of anti-inflammatory compounds, especially for the pharmacogenetic association of responsiveness to rheumatoid arthritis medications that target TNF?.

Abstract: The present invention provides methods for the early prediction of aging-related dermatologic conditions of including skin changes associated with intrinsic aging or skin damages caused by extrinsic aging such as photoaging. The present invention also provides kits for the early determination of the propensity to develop such disorder and conditions. The method consists of detecting the presence of one or more alleles of an IL-1 haplotype or pattern, specifically the IL-1RN (+2018) and the IL-1B (?511) loci. The presence of allele 2 at the IL-1RN (+2018) and the IL-1B (?511) loci indicates decreased risk for a early onset of aging related dermatologic conditions.

Abstract: Methods and kits for determining whether a subject has or is predisposed to developing restenosis are provided.

Abstract: Diagnostics and therapeutics for osteoporosis, which are based on the identification of the subject's IL-1 haplotype pattern are described.

Abstract: Methods and kits for detecting polymorphisms that are predictive of a subject's susceptibility to developing an obstructive airway disease, such as asthma, as well as for determining the relative severity of the disease are described. Assays for identify therapeutics are also described.

Abstract: Methods, assays and kits are disclosed for detecting a mother's or a fetus's susceptibility to an adverse pregnancy outcome such as low birth weight. The methods comprise obtaining a biological sample from a patient and determining the presence or absence of an IL-1 allele 2 of a marker that is associated with an adverse pregnancy outcome.

Abstract: A method of predicting whether a subject is predisposed to developing early-onset menopause is provided. The method involves genotyping a patient at the IL-1 gene loci.

Abstract: Methods and kits for determining whether a subject has or is predisposed to developing restenosis are provide.